Replies to post #205313 on Biotech Values

[DewDiligence]

Bayer’s mid/late-stage drug pipeline:

http://epvantage.com/Universal/View.aspx?type=Story&id=689760&isEPVantage=yes

Note: If the MON buyout goes through, Bayer’s ag (“Crop Sciences”) division will account for more than 50% of the company’s sales.